vs
Chatham Lodging Trust（CLDT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Chatham Lodging Trust的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$67.7M vs $35.5M），Chatham Lodging Trust净利率更高（6.8% vs -304.2%，领先311.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -9.8%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -0.5%）
查塔姆住宿信托是一家专注于投资、持有及运营高端长住型和精选服务类酒店物业的房地产投资信托，主要布局美国高需求的城市及城郊市场，服务商务与休闲旅客群体，追求长期稳定的现金流收益。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CLDT vs RXRX — 直观对比
营收规模更大
CLDT
是对方的1.9倍
$35.5M
营收增速更快
RXRX
高出691.6%
-9.8%
净利率更高
CLDT
高出311.0%
-304.2%
两年增速更快
RXRX
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.7M | $35.5M |
| 净利润 | $4.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 15.9% | -304.8% |
| 净利率 | 6.8% | -304.2% |
| 营收同比 | -9.8% | 681.7% |
| 净利润同比 | 369.9% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDTRXRX
| Q4 25 | $67.7M | $35.5M | ||
| Q3 25 | $78.4M | $5.2M | ||
| Q2 25 | $80.3M | $19.2M | ||
| Q1 25 | $68.6M | $14.7M | ||
| Q4 24 | $75.1M | $4.5M | ||
| Q3 24 | $87.2M | $26.1M | ||
| Q2 24 | $86.5M | $14.4M | ||
| Q1 24 | $68.4M | $13.8M |
净利润CLDTRXRX
| Q4 25 | $4.6M | $-108.1M | ||
| Q3 25 | $3.5M | $-162.3M | ||
| Q2 25 | $5.4M | $-171.9M | ||
| Q1 25 | $1.5M | $-202.5M | ||
| Q4 24 | $-1.7M | $-178.9M | ||
| Q3 24 | $4.3M | $-95.8M | ||
| Q2 24 | $6.8M | $-97.5M | ||
| Q1 24 | $-5.2M | $-91.4M |
毛利率CLDTRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | 40.7% | -181.4% | ||
| Q3 24 | 44.7% | 53.7% | ||
| Q2 24 | 46.1% | 36.2% | ||
| Q1 24 | 38.9% | 19.1% |
营业利润率CLDTRXRX
| Q4 25 | 15.9% | -304.8% | ||
| Q3 25 | 12.7% | -3327.6% | ||
| Q2 25 | 14.8% | -916.8% | ||
| Q1 25 | 12.1% | -1297.9% | ||
| Q4 24 | 7.5% | -4042.4% | ||
| Q3 24 | 14.3% | -377.1% | ||
| Q2 24 | 16.3% | -697.4% | ||
| Q1 24 | 1.4% | -698.4% |
净利率CLDTRXRX
| Q4 25 | 6.8% | -304.2% | ||
| Q3 25 | 4.5% | -3135.3% | ||
| Q2 25 | 6.7% | -894.2% | ||
| Q1 25 | 2.2% | -1373.3% | ||
| Q4 24 | -2.3% | -3935.5% | ||
| Q3 24 | 4.9% | -367.5% | ||
| Q2 24 | 7.9% | -676.6% | ||
| Q1 24 | -7.6% | -662.4% |
每股收益（稀释后）CLDTRXRX
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $0.03 | $-0.36 | ||
| Q2 25 | $0.07 | $-0.41 | ||
| Q1 25 | $-0.01 | $-0.50 | ||
| Q4 24 | $-0.08 | $-0.56 | ||
| Q3 24 | $0.05 | $-0.34 | ||
| Q2 24 | $0.10 | $-0.40 | ||
| Q1 24 | $-0.15 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.4M | $743.3M |
| 总债务越低越好 | $338.9M | $9.6M |
| 股东权益账面价值 | $740.8M | $1.1B |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.46× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CLDTRXRX
| Q4 25 | $24.4M | $743.3M | ||
| Q3 25 | $13.2M | $659.8M | ||
| Q2 25 | $17.2M | $525.1M | ||
| Q1 25 | $18.6M | $500.5M | ||
| Q4 24 | $20.2M | $594.4M | ||
| Q3 24 | $19.3M | $427.6M | ||
| Q2 24 | $10.6M | $474.3M | ||
| Q1 24 | $72.3M | $296.3M |
总债务CLDTRXRX
| Q4 25 | $338.9M | $9.6M | ||
| Q3 25 | $338.8M | $11.9M | ||
| Q2 25 | $351.2M | $14.2M | ||
| Q1 25 | $381.1M | $16.4M | ||
| Q4 24 | $406.9M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CLDTRXRX
| Q4 25 | $740.8M | $1.1B | ||
| Q3 25 | $749.4M | $1.0B | ||
| Q2 25 | $754.1M | $919.1M | ||
| Q1 25 | $754.7M | $933.9M | ||
| Q4 24 | $758.2M | $1.0B | ||
| Q3 24 | $765.3M | $524.6M | ||
| Q2 24 | $766.5M | $584.4M | ||
| Q1 24 | $765.0M | $401.2M |
总资产CLDTRXRX
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $726.5M | ||
| Q2 24 | $1.3B | $775.9M | ||
| Q1 24 | $1.3B | $557.8M |
负债/权益比CLDTRXRX
| Q4 25 | 0.46× | 0.01× | ||
| Q3 25 | 0.45× | 0.01× | ||
| Q2 25 | 0.47× | 0.02× | ||
| Q1 25 | 0.50× | 0.02× | ||
| Q4 24 | 0.54× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $64.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 13.90× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CLDTRXRX
| Q4 25 | $64.1M | $-46.1M | ||
| Q3 25 | $25.6M | $-117.4M | ||
| Q2 25 | $22.1M | $-76.4M | ||
| Q1 25 | $4.2M | $-132.0M | ||
| Q4 24 | $73.8M | $-115.4M | ||
| Q3 24 | $28.8M | $-59.2M | ||
| Q2 24 | $25.2M | $-82.2M | ||
| Q1 24 | $6.9M | $-102.3M |
自由现金流CLDTRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率CLDTRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度CLDTRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率CLDTRXRX
| Q4 25 | 13.90× | — | ||
| Q3 25 | 7.24× | — | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 2.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDT
| Occupancy | $61.5M | 91% |
| Hotel Other | $4.2M | 6% |
| Food And Beverage | $1.8M | 3% |
| Hotel | $1.1M | 2% |
RXRX
暂无分部数据
